Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

Does rivaroxaban have a role in treating patients with PAD?

Thomas, Rebekah PharmD, PA-C, BCPS, BC-ADM

Journal of the American Academy of PAs: July 2019 - Volume 32 - Issue 7 - p 16–17
doi: 10.1097/01.JAA.0000558364.85986.ad
Pharmacology Consult
Buy

ABSTRACT Peripheral arterial disease can cause devastating health outcomes, and few therapies are available to treat this condition. Results of a secondary analysis of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily. This treatment regimen could change the standard pharmacotherapeutic management practice for many patients with peripheral arterial disease.

Rebekah Thomas is assistant program director, Georgia campus site director, and an assistant professor in the PA program at Philadelphia College of Osteopathic Medicine in Suwanee, Ga. The author has disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website